A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

MLA

Garzon, Ramiro, et al. “A Phase 1 Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia.” Blood, vol. 129, no. 24, June 2017, pp. 3165–74. EBSCOhost, https://doi.org/10.1182/blood-2016-11-750158.

APA

Garzon, R., Savona, M., Baz, R., Andreeff, M., Gabrail, N., Gutierrez, M., Savoie, L., Mau-Sorensen, P. M., Wagner-Johnston, N., Yee, K., Unger, T. J., Saint-Martin, J.-R., Carlson, R., Rashal, T., Kashyap, T., Klebanov, B., Shacham, S., Kauffman, M., & Stone, R. (2017). A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood, 129(24), 3165–3174. https://doi.org/10.1182/blood-2016-11-750158

Chicago

Garzon, Ramiro, Michael Savona, Rachid Baz, Michael Andreeff, Nashat Gabrail, Martin Gutierrez, Lynn Savoie, et al. 2017. “A Phase 1 Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia.” Blood 129 (24): 3165–74. doi:10.1182/blood-2016-11-750158.